Drugs.com - FDA MedWatch Alerts

FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns

Audience: Health Care Professionals, Patients September 26, 2024 -- FDA is alerting patients, caregivers, and health care professionals that Oxbryta (voxelotor) is being voluntarily withdrawn from the market by the manufacturer due to safety...

Apr 26, 2025 - 14:23
 0
FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta from the Market Due to Safety Concerns
Audience: Health Care Professionals, Patients September 26, 2024 -- FDA is alerting patients, caregivers, and health care professionals that Oxbryta (voxelotor) is being voluntarily withdrawn from the market by the manufacturer due to safety...
Read More

Tags:

Previous Article

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

Next Article

Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury (Remdesivir) for...

Related Posts

Natural Dior LLC Issues Voluntary Nationwide Recall of Vitafer-L Gold Liquid Due to Presence of Undeclared Tadalafil

Natural Dior LLC Issues Voluntary Nationwide Recall of ...

Apr 26, 2025  0

Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System

Alvogen Issues Voluntary Nationwide Recall for One Lot ...

Apr 26, 2025  0

Boulla LLC Issues Voluntary Nationwide Recall of ZoomMax and ZapMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac

Boulla LLC Issues Voluntary Nationwide Recall of ZoomMa...

Apr 26, 2025  0